Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group BEFREE We analyzed data on the expressions of phosphorylated AKT1 and MYC and the concentrations of 228 metabolites from 60 human prostate tumor samples and 16 normal tissue samples. 30340213 2018
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group CTD_human Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. 29295717 2018
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group CTD_human Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. 23704919 2013
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group BEFREE Behavioral stress inhibited apoptosis and delayed prostate tumor involution both in phosphatase and tensin homolog-deficient (PTEN-deficient) prostate cancer xenografts treated with PI3K inhibitor and in prostate tumors of mice with prostate-restricted expression of c-MYC (Hi-Myc mice) subjected to androgen ablation therapy with bicalutamide. 23348742 2013
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group BEFREE On the basis of our results, we conclude that elevated C-MYC expression in primary prostate tumor is biologically relevant and may be a predictor of future biochemical recurrence. 20820186 2010
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group BEFREE Analysis of MYC and the mTOR pathway in human prostate tumors and PrEC showed selective increased expression of eukaryotic initiation factor 4E-binding protein 1 (4EBP1) with gain in MYC copy number or forced MYC expression, respectively. 19773438 2009
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group LHGDN Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells. 18623111 2009
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group LHGDN Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. 18567993 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group BEFREE Expression profiling analysis and modeling of transcriptional regulatory networks predicts a functional association between MYC and the prostate tumor suppressor KLF6. 18190704 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 GeneticVariation group LHGDN Expression profiling analysis and modeling of transcriptional regulatory networks predicts a functional association between MYC and the prostate tumor suppressor KLF6. 18190704 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 GeneticVariation group LHGDN Multiple independent genetic variants in the 8q24 region are associated with prostate cancer risk. 18483343 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group BEFREE Taken together, these data combining cell culture and animal models and human prostate tumors reveal that ERG overexpression in prostate tumor cells may contribute to the neoplastic process by activating C-MYC and by abrogating prostate epithelial differentiation as indicated by prostate epithelial specific markers. 18542058 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group LHGDN Does the inhibition of c-myc expression mediate the anti-tumor activity of PPAR's ligands in prostate cancer cell lines? 17466258 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group CTD_human Integrative molecular concept modeling of prostate cancer progression. 17173048 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group LHGDN Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. 15937962 2005